business
TuHURA Biosciences Receives FDA IND Clearance For TBS-2025 In AML
TuHURA Biosciences (HURA) received FDA clearance for its IND application for TBS-2025, a VISTA-inhibiting antibody for relapsed/refractory mutNPM1 AML. The Phase 1b study will evaluate TBS-2025 as monotherapy in patients who failed menin inhibitor therapy.
Read full article on Rttnews